Wednesday, May 3, 2023
CONTINENTAL BREAKFAST
8:00 - 9:00
Introduction to the Programme
Harley Eisman, MD, Co-Founder, Hereditary Breast and Ovarian Cancer Foundation, Montréal, QC, Canada
William Foulkes, MBBS, PhD, Director, Program in Cancer Genetics,
McGill University, Montréal, QC, Canada
The breast cancer genes:
How to implement what we know and
what to expect next
CHAIR: Britta Weigelt, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, USA
9:15 - 9:35
LECTURE
CanRisk: personalising cancer risk prediction for
prevention and early detection
Antonis Antoniou, PhD, University of Cambridge, Cambridge, UK
9:35 - 9:55
LECTURE
The breast cancer susceptibility gene scorecard:
What is in, what is out and what is left to find?
Clare Turnbull, MD, PhD, MFPH, Institute of Cancer Research, London, UK
9:55 - 10:05
PROFFERED PAPER 1 (S4-PP1)
Finding new causes of hereditary breast cancer: resolving the role of inherited promoter hypermethylation in known hereditary breast cancer genes and mutations in non-coding regions of BRCA1, BRCA2 and PALB2
Ian G Campbell, PhD, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
10:05 - 10:15
PROFFERED PAPER 2 (S4-PP2)
Multiplexed assays of variant effect for all possible missense alterations located in the DNA Binding Domain of BRCA2
Fergus Couch, PhD, Fergus Couch, PhD, Mayo Clinic, Rochester, MN, United States
10:17 - 10:20
RAPID FIRE POSTER PRESENTATIONS (S4-RF1)
Poster # P059: Exome sequencing identifies novel susceptibility genes and defines the contribution of coding variants to breast cancer risk
Naomi Wilcox, PhD student, University of Cambridge, Cambridge, UK
10:20 - 10:23
RAPID FIRE POSTER PRESENTATIONS (S4-RF2)
Poster # P083: Universal whole genome tumour and germline sequencing of newly diagnosed breast cancer
Ian G Campbell, PhD, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
10:25 - 10:45
Question and discussion period (all speakers)
New approaches to the early diagnosis of hereditary cancers
CHAIR: Alan Spatz, MD, MSc, McGill University, Montréal, QC, Canada
11:15 - 11:35
LECTURE
Li-Fraumeni as a case study of the effect of early diagnosis on outcomes
David Malkin, MD, FRCPC, The Hospital for Sick Children (SickKids), Toronto, ON, Canada
11:35 - 11:55
LECTURE
Hereditary Cancer Surveillance Using Cell-free DNA Sequencing
Trevor Pugh, PhD, FACMG, Ontario Institute for Cancer Research (OICR), Toronto, ON, Canada
11:55 - 12:05
PROFFERED PAPER 1 (S5-PP1)
Increase in tumor DNA testing during nationwide implementation of the Tumor-First workflow to optimize identification of heredity in epithelial ovarian cancer
Vera M. Witjes, PhD candidate, Radboud University Medical Center, Nijmegen, The Netherlands
12:05 - 12:15
PROFFERED PAPER 2 (S5-PP2)
MRI surveillance and breast cancer mortality in BRCA1 and BRCA2 mutation carriers
Steven Narod, MD, Women’s College Research Institute, Women’s College Hospital, Toronto, ON, Canada
12:17 - 12:20
RAPID FIRE POSTER PRESENTATIONS (S5-RF1)
Somatic testing lags far behind germline testing in patients with epithelial ovarian cancer; a missed opportunity
Kayla Ostiller, MD, Kaiser Permanente San Francisco, CA, United States
12:20 - 12:23
RAPID FIRE POSTER PRESENTATIONS (S5-RF2)
Facilitated cascade testing for families with identified variants associated with hereditary gynecologic cancers
Sarah S. Lee, MD, NYU Langone Health, New York, NY, United States
12:25 - 12:45
Question and discussion period (all speakers)
LUNCH BREAK
12:45 - 14:15
Special Interest Groups (SIGs)
Moderated 90-minute interactive discussions with the aim of fostering bilateral knowledge transfer. Choice of one of the following 3 SIGs.
SIG 1:
Other BRCA-associated Cancers (pancreas and prostate):
Germline Testing, Early Detection and Targeted Cancer Therapies
This session will focus on the evidence and recommendations for 1) germline testing in incident cases of pancreatic and prostate cancers, 2) surveillance of germline BRCA2, BRCA1 and PALB2 mutation carriers for early detection of pancreatic and prostate cancers, and 3) targeted therapies in patients with pancreatic and prostate cancers driven by BRCA2, BRCA1 or PALB2 mutations. Attendees will be encouraged to send in questions relating to these topics in advance for discussion at the SIG.
George Zogopoulos, MD, PhD, McGill University Health Centre, Montréal, QC, Canada
Daniel Vesprini, MD, MSc, FRCPC, Sunnybrook Odette Cancer Centre, Toronto, ON, Canada
SIG 2:
Professional ethical duty and liability in a context of increasing decentralization and de-specialisation of genetic tests
The use of genetic tests for precision oncology has increased considerably, propelled by rapid scientific advances in genomics and the popularity of direct-to-consumer services. To meet this increasing demand, we have seen emerge a phenomenon of decentralization and de-specialisation of genetic testing in healthcare systems. The current session will cover some of the principal issues raised by this new genetic testing context and propose innovative solutions to address them.
Yann Joly, PhD, AdE McGill University, Montréal, QC, Canada (session lead)
David J. Peloquin, JD, Ropes & Gray, Boston, MA, USA
Yvonne Bombard, PhD, BSc, Li Ka Shing Knowledge Institute, St Michael’s Hospital, Toronto, ON, Canada
SIG 3:
Cancer Concerns for Transgender and Gender Diverse People
In this session, the three presenters will lead a discussion regarding cancer risks among transgender / gender diverse (TGD) people along with barriers to cancer surveillance and treatment, including considerations regarding BRCA testing for breast cancer risk in TGD people. The discussion will include risks associated with typical gender affirming medical interventions and risks associated with the myriad barriers to cancer care for TGD people. Attendees will be encouraged to submit questions in advance to help inform the conversation.
Joshua D. Safer, MD, Mount Sinai Center for Transgender Medicine and Surgery, Mount Sinai Health System, New York, NY, USA (session lead)
Sharon Bober – PhD, Dana-Farber Cancer Institute/Harvard Medical School, Boston, MA, USA
Special Round Table: Disparities in Hereditary Cancer Genetics – What are we
doing to improve the situation?
MODERATORS:
Lawrence Brody, PhD, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA;
Laurence Baret, MA, MSc, CCGC, CGC, McGill University, Montréal, QC, Canada
Tuya Pal, MD, Vanderbilt – Ingram Cancer Center, Nashville, TN, USA
Yvonne Bombard, PhD, BSc, Li Ka Shing Knowledge Institute, St Michael’s Hospital, Toronto, ON, Canada
Funmi Olopade, MD, FACP, OON, Center for Clinical Cancer Genetics, University of Chicago Medicine, Chicago, IL, USA
Grace-Ann Fasaye, ScM, CGC, Genetics Branch of the Center for Cancer Research at the National Cancer Institute (NCI), Bethesda, MD, USA